Your Heart Runs on a Clock — and Ignoring It Can Be Deadly
A major 2025 review reveals how circadian rhythms govern heart attack timing, heart failure, arrhythmias, and whether your treatments actually work.
Summary
A comprehensive 2025 review in the European Heart Journal synthesizes evidence showing that circadian rhythms — governed by the brain's suprachiasmatic nucleus and peripheral tissue clocks — profoundly shape cardiovascular disease risk, timing, and severity. Heart attacks cluster in the morning when sympathetic tone, blood pressure, and platelet aggregation peak. Infarct size varies by time of day. Heart failure and arrhythmias follow distinct 24-hour patterns. Circadian disruptions from shift work, sleep deprivation, and irregular eating amplify cardiovascular risk. Chronotherapy — timing drugs and interventions to align with biological rhythms — shows real promise for improving outcomes in hypertension, anticoagulation, and cardiac surgery.
Detailed Summary
Cardiovascular disease does not strike randomly across the clock. A landmark 2025 review in the European Heart Journal by Kelters, Koop, Young, Daiber, and van Laake synthesizes decades of circadian biology research to show that the heart and vasculature operate on tightly regulated 24-hour programs — and that disrupting these rhythms carries serious consequences.
At the molecular level, core clock proteins (CLOCK, BMAL1, PER1/2/3, CRY1/2, REV-ERBα/β, RORα/β/γ) drive transcriptional-translational feedback loops that oscillate gene expression across all cardiovascular tissues. These molecular rhythms govern myocardial contractility, vascular tone, endothelial function, coagulation, metabolism, and autonomic balance. During sleep, parasympathetic dominance lowers heart rate and blood pressure, supporting cardiac recovery. At waking, sympathetic activation surges — a transition that coincides with the highest daily risk of myocardial infarction (MI).
The clinical evidence is striking. MI incidence is roughly three times higher in the morning than late evening, and STEMI is about 10% more common in the morning than afternoon or night. Infarct size is also time-dependent: the largest infarcts and worst left ventricular function occur in the early morning hours, confirmed across multiple imaging and biomarker studies including an analysis of 1,031 STEMI patients. Daylight saving time transitions — particularly the spring shift — are associated with increased non-STEMI incidence for up to three weeks, with women showing greater susceptibility. Sudden cardiac death peaks in the morning; atrial fibrillation onset is more frequent at night. Heart failure patients retain circadian rhythmicity, though dampened, suggesting preserved targets for timing-based interventions.
Risk amplifiers including shift work, sleep deprivation, obesity, diabetes, psychological stress, light pollution, and irregular eating patterns disrupt molecular clock pathways, compounding cardiovascular vulnerability. Evening chronotypes face disproportionate risk due to misalignment between internal rhythms and social schedules. Oxidative stress, inflammation, and autonomic dysregulation mediate much of this circadian-disruption-driven pathology.
Chronotherapy emerges as a clinically actionable strategy. Timing antihypertensives, anticoagulants, statins, and cardiac surgical interventions to align with circadian biology has demonstrated measurable improvements in efficacy and outcomes. The review calls for systematic recording of time-of-day in clinical interventions, time-adjusted laboratory reference ranges, and standardized circadian protocols in drug development. Caveats include the predominance of observational data, inconsistencies across study designs, and the need for prospective randomized chronotherapy trials.
Key Findings
- MI incidence is ~3× higher in the morning; STEMI is ~10% more common morning vs. night.
- Infarct size and LV dysfunction are worst in early morning hours across multiple clinical studies.
- Sudden cardiac death peaks in the morning; atrial fibrillation onset clusters more often at night.
- Daylight saving time spring transition increases non-STEMI risk for ~3 weeks, more pronounced in women.
- Chronotherapy — timing drugs and procedures to circadian rhythms — shows measurable clinical benefit.
Methodology
This is a narrative review published in the European Heart Journal (2025), synthesizing preclinical and clinical literature on circadian rhythms and cardiovascular disease. The authors reviewed evidence across ischaemic heart disease, heart failure, arrhythmias, and chronotherapy, with supplemental tables cataloguing time-of-day incidence data across multiple studies.
Study Limitations
The review is narrative rather than systematic, introducing potential selection bias. Many underlying studies are observational, limiting causal inference. Prospective randomized trials of chronotherapy in cardiovascular disease remain limited, and translating nocturnal animal model findings to human diurnal rhythms requires caution.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.